Short-term efficacy of intravitreal bevacizumab for the treatment of macular edema due to diabetic retinopathy and retinal vein occlusion

被引：11
作者：
Astam N. [1 ,2 ]
Batioǧlu F. [1 ]
Özmert E. [1 ]
机构：
[1] Department of Ophthalmology, Ankara University School of Medicine, Ankara
[2] Kurtuluş, Ankara
来源：
International Ophthalmology | 2009年 / 29卷 / 5期
关键词：
Diabetic retinopathy; Intravitreal bevacizumab; Macular edema; Retinal vein occlusion;
D O I：
10.1007/s10792-008-9242-2
中图分类号：
学科分类号：
摘要：
Purpose: To evaluate the short-term efficacy of intravitreal bevacizumab injection for the management of macular edema due to diabetic retinopathy and retinal vein occlusion. Methods: Patients with macular edema due to diabetic retinopathy, and retinal vein occlusion were treated with intravitreal bevacizumab and evaluated retrospectively. Standardized ophthalmic evaluation, ETDRS visual acuity measurement, and central macular thickness were performed at baseline and 1 month intervals after injection. Results: There were 23 eyes of 21 patients with macular edema due to diabetic retinopathy (14 eyes of 12 patients), and retinal vein occlusion (9 eyes of 9 patients). The mean baseline logMAR visual acuity and central macular thickness were 0.82 ± 0.27 and 604.71 ± 123.62 μm, respectively, in patients with diabetic retinopathy. There was no statistically significant difference between the mean logMAR visual acuity (P = 0.22) and central retinal thickness (P = 0.16) measurements at baseline and 3 months follow-up. The mean baseline logMAR visual acuity and central macular thickness were 0.94 ± 0.48 and 557 ± 113.9 μm, respectively, in patients with retinal vein occlusion. There was a statistically significant difference between the mean logMAR visual acuity and central retinal thickness measurements at baseline and 3 months follow-up (P < 0.01). Almost all of the eyes (88.8%) regained normal foveal configuration. Conclusions: Although our follow-up period was short and the number of patients were limited to provide specific treatment recommendations, intravitreal bevacizumab seems to be more effective for macular edema due to retinal vein occlusion than diabetic macular edema. The favorable short-term results suggest further study is needed. © Springer Science+Business Media B.V. 2008.
引用
收藏
页码：343 / 348
页数：5
相关论文
共 14 条
[1]  
Tranos P.G., Pavesio C.E., Macular edema, Surv Ophthalmol, 49, 5, pp. 470-490, (2004)
[2]  
Adamis A.P., Miller J.W., Bernal M.T., Et al., Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy, Am J Ophthalmol, 118, pp. 445-450, (1994)
[3]  
Gragoudas E.S., Adamis A.P., Et al., VEGF inhibition study in ocular neovascularization clinical trial group. Pegaptanib for neovascular AMD, N Engl J Med, 351, pp. 2805-2816, (2004)
[4]  
Avery R.L., Pieramici D.J., Rabena M.D., Et al., Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration, Ophthalmology, 113, pp. 363-372, (2006)
[5]  
Rosenfeld P.J., Fung A.E., Puliafito C.A., OCT finding after intravitreal injection of bevacizumab for macular edema for central retinal vein occlusion, Ophthalmic Surg Lasers Imaging, 36, pp. 336-339, (2005)
[6]  
Rosenfeld P.J., Moshfeghi A.A., Puliafito C.A., OCT findings after intravitreal injection of bevacizumab (Avastin) for neovascular age - Related macular degeneration, Ophthalmic Surg Laser Imaging, 36, pp. 270-271, (2005)
[7]  
Haritoglou C., Kook D., Neubauer A., Et al., Intravitreal bevacizumab (avastin) therapy for persistent diffuse diabetic macular edema, Retina, 26, pp. 999-1005, (2006)
[8]  
Iturralde D., Spaide R., Meyele C., Et al., Intravitreal bevacizumab (Avastin) treatment of macular edema in CRVO. A short-term study, Retina, 26, pp. 279-284, (2006)
[9]  
Shahar J.S., Aury R.L., Heilweil G., Et al., Electrophysiologic and retinal penetration studies following intravitreal injection of bevacizumab, Retina, 26, pp. 262-269, (2006)
[10]  
A phase II randomized double-masked study of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema, Ophthalmology, 112, pp. 1747-1757, (2005)
12